SCHEMBL8088644

SCHEMBL8088644

CCOC(=O)NC(CN)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAD P27708 1/20 0.39
ATM Q13315 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGAV P06756 1/20 0.38
GAA P10253 2/20 0.37
ALOX15 P16050 2/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
MAPK1 P28482 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
NOD1 Q9Y239 2/20 0.35
TGFBR1 P36897 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 2/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8142588 1.00 CAD (0.39) CADATMITGB3ITGAVGAA
SCHEMBL8088672 0.85 ALDH1A1 (0.37) ITGB3SMN1; SMN2MAPK1LMNANOD1
SCHEMBL9830204 0.84 ATM (0.40) CADATMITGB3ITGAVGAA
SCHEMBL28009494 0.82 TGFBR1 (0.53) CADATMITGB3ITGAVGAA
SCHEMBL17224588 0.82 TGFBR1 (0.53) CADATMITGB3ITGAVGAA
SCHEMBL28710585 0.82 TGFBR1 (0.53) CADATMITGB3ITGAVGAA
SCHEMBL30202144 0.82 EPHX1 (0.43) ITGB3SMN1; SMN2NOD1L3MBTL1ALDH1A1
SCHEMBL9716671 0.82 FOLH1 (0.47) ITGB3NOD1CYP1A2FOLH1
SCHEMBL9716665 0.82 FOLH1 (0.47) ITGB3NOD1CYP1A2FOLH1
SCHEMBL7368743 0.82 EPHX1 (0.43) ITGB3SMN1; SMN2NOD1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1051625-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES Du Pont Pharmaceuticals Company (US) 2000-11-15 EP disclosed
WO-1999038014-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-29 WO disclosed